

Analysis of Reddit Discourse on Novel Dementia Treatments: A Retrospective Observational Study

13454

Zain Hussain, Mysha Sajid, Muhammed Shaan Riaz, Ayaz Sajid, Filippo Queirazza, Fani Deligianni, Amir Hussain, Aziz Sheikh, Craig W. Ritchie, Jonathan Cavanagh

Analysis of 1,525 Reddit posts across 695 subreddits identified distinct treatment-specific discourse profiles. Approved anti-amyloid therapies were characterised by discussion of regulatory approval, safety monitoring, and caregiver help-seeking; GLP-1 agonists by contested narratives around metabolic-cognitive risk and disappointment following negative Alzheimer's disease trial results; and pipeline therapies by heterogeneous longevity- and biotech-driven discussion. Sentiment was broadly positive across treatment categories (59%–67%), although GLP-1 discourse was the least positive (mean VADER compound score: 0.266 vs 0.318 for anti-amyloid therapies and 0.345 for pipeline therapies).

| INTRODUCTION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | METHODS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | RESULTS                                 | CONCLUSIONS                           | REFERENCES                                                                                                                                                                                                                                                                                                                                  |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-------------------------------|-----|-----|-----|----------------------------------|----|-----|----|--------------------------|----|-----|-----|----------------------------------|----|----|-----|------------------------------|----|----|----|--------------------|----|----|----|---------------------------------|----|----|----|--------------------------------|----|-----|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------|-------------|--------------|------------------------|-----|----|-----|------------------------------|-----|----|-----|----------------------------|-----|-----|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Novel disease-modifying Alzheimer's disease therapies have entered clinical practice at a time of high public interest and contested evidence. The approval of lecanemab (2023) and donanemab (2024), the emergence of GLP-1 receptor agonists as potential neuroprotective therapies, and an active pipeline of tau-targeting agents have created a treatment landscape whose online public discourse remains poorly characterised. Reddit, with over 100,000 topic-specific communities, provides large-scale, unmediated discourse that may complement conventional qualitative methods by identifying public concerns at scale and speed. Online discourse analysis has been proposed as a tool for hypothesis generation, communication strategy development, and trial recruitment support in dementia research.</p> <p><b>Objectives</b></p> <ul style="list-style-type: none"><li>To characterise the volume, sentiment, and thematic profile of Reddit discourse across three a priori treatment categories</li><li>To identify whether discourse themes differ by treatment category using unsupervised topic modelling</li><li>To evaluate Reddit discourse analysis as a complement to conventional qualitative dementia research</li></ul> | <p><b>Study design:</b> Retrospective observational study. Posts collected January 2022 - March 2026 via Reddit's public JSON endpoint (Python).</p> <p><b>Categories (a priori keyword-defined):</b><br/>Category A: Approved anti-amyloid antibodies: lecanemab, donanemab, aducanumab<br/>Category B: GLP-1 agonists co-occurring with dementia terms: semaglutide, tirzepatide, Ozempic<br/>Category C: Pipeline/emerging agents: trontinemab, simufilam, tau-targeting antibodies</p> <p><b>Analysis:</b> Sentiment: VADER lexicon-based compound sentiment analysis (positive ≥0.05; negative ≤−0.05)<br/>Discourse themes: Latent Dirichlet Allocation, category-specific, deduplicated corpus<br/>Between-category comparisons: Kruskal-Wallis H-test; Mann-Whitney U with Bonferroni correction.<br/><b>Ethics:</b> Secondary analysis of publicly available, non-identifiable data; no formal review required.</p> <div><p><b>LDA Topic Distribution by Treatment Category</b></p><table><tr><th></th><th>Category A<br/>Anti-amyloid<br/>(n=733)</th><th>Category B<br/>GLP-1 Agonists<br/>(n=347)</th><th>Category C<br/>Pipeline<br/>(n=445)</th></tr><tr><td>Core AD clinical &amp; scientific</td><td>57%</td><td>10%</td><td>29%</td></tr><tr><td>GLP-1 / metabolic risk discourse</td><td>9%</td><td>48%</td><td>6%</td></tr><tr><td>Lifestyle / brain health</td><td>4%</td><td>12%</td><td>17%</td></tr><tr><td>Cellular / immune &amp; inflammation</td><td>8%</td><td>3%</td><td>19%</td></tr><tr><td>Medicare / access &amp; coverage</td><td>6%</td><td>3%</td><td>0%</td></tr><tr><td>APOE4 genetic risk</td><td>4%</td><td>0%</td><td>0%</td></tr><tr><td>General public health &amp; science</td><td>4%</td><td>4%</td><td>8%</td></tr><tr><td>Personal narrative &amp; caregiver</td><td>8%</td><td>20%</td><td>21%</td></tr></table></div> <p><b>Figure 2.</b> Category-specific discourse themes identified using Latent Dirichlet Allocation (LDA).</p> |                                         | Category A<br>Anti-amyloid<br>(n=733) | Category B<br>GLP-1 Agonists<br>(n=347)                                                                                                                                                                                                                                                                                                     | Category C<br>Pipeline<br>(n=445) | Core AD clinical & scientific | 57% | 10% | 29% | GLP-1 / metabolic risk discourse | 9% | 48% | 6% | Lifestyle / brain health | 4% | 12% | 17% | Cellular / immune & inflammation | 8% | 3% | 19% | Medicare / access & coverage | 6% | 3% | 0% | APOE4 genetic risk | 4% | 0% | 0% | General public health & science | 4% | 4% | 8% | Personal narrative & caregiver | 8% | 20% | 21% | <p>1,525 posts retained across 695 unique subreddits (A: n=733; B: n=347; C: n=445). Sentiment analysis findings are illustrated in Figure 1.</p> <p><b>Engagement:</b> Category B generated the highest mean comments per post (14.7 vs 11.4 and 8.5 for A and C respectively) and highest mean upvote score (98.7 vs 78.2 and 39.1).</p> <p><b>Discourse themes (Figure 2):</b> Category-specific LDA revealed distinct topic profiles. Anti-amyloid discourse dominated by core clinical/scientific content (57%) with distinct sub-themes around regulatory approval and access (including Medicare coverage of aducanumab), ARIA safety monitoring, and caregiver narrative layer (8%). GLP-1 discourse characterised by metabolic-cognitive risk framing (48%) personal narratives (20%) and a discrete failed-trial disappointment theme. Pipeline discourse was heterogeneous, distributed across cellular/immune mechanisms (19%), lifestyle and longevity framing (17%), and personal narrative (21%).</p> <div><p><b>VADER Sentiment Distribution by Treatment Category</b></p><table><tr><th>Category</th><th>Positive (%)</th><th>Neutral (%)</th><th>Negative (%)</th></tr><tr><td>Cat C Pipeline (n=445)</td><td>67%</td><td>4%</td><td>30%</td></tr><tr><td>Cat B GLP-1 Agonists (n=347)</td><td>59%</td><td>8%</td><td>33%</td></tr><tr><td>Cat A Anti-amyloid (n=733)</td><td>64%</td><td>14%</td><td>22%</td></tr></table></div> <p><b>Figure 1.</b> Sentiment profile of Reddit discussions across treatment categories. Distribution of sentiment classifications and mean VADER compound scores</p> | Category | Positive (%) | Neutral (%) | Negative (%) | Cat C Pipeline (n=445) | 67% | 4% | 30% | Cat B GLP-1 Agonists (n=347) | 59% | 8% | 33% | Cat A Anti-amyloid (n=733) | 64% | 14% | 22% | <ul style="list-style-type: none"><li>Online discourse on novel Alzheimer's disease treatments differed substantially by treatment category and community context.</li><li>Approved anti-amyloid therapies were associated with discourse centred on regulatory access, safety monitoring, and caregiver help-seeking, themes directly relevant to clinical communication and post-marketing surveillance.</li><li>GLP-1 agonist discourse was the most contested, reflecting an evidence base in flux: metabolic-cognitive risk narratives coexisted with disappointment linked to null trial results, and discourse spanned weight-loss, diabetes, and neuroscience communities.</li><li>Pipeline discourse was heterogeneous and community-driven, reflecting longevity and biotech interest rather than patient-facing need.</li><li>Our findings support the utility of Reddit discourse analysis as a hypothesis-generating complement to conventional qualitative research, and may inform targeted communication strategies and trial recruitment.</li><li>Interpretation requires caution given platform-specific sampling and the use of lexicon-based sentiment analysis, which may underperform on nuanced or ironic health discourse.</li></ul> | <ol style="list-style-type: none"><li>Blei DM, Ng AY, Jordan MI. Latent Dirichlet Allocation. <i>J Mach Learn Res.</i> 2003;3:993–1022. Franzke AS,</li><li>Bechmann A, Zimmer M, Ess C; Association of Internet Researchers. Internet Research: Ethical Guidelines 3.0. Association of Internet Researchers; 2020.</li><li>Hutto CJ, Gilbert E. VADER: A Parsimonious Rule-Based Model for Sentiment Analysis of Social Media Text. In: <i>Proceedings of the 8th International AAAI Conference on Weblogs and Social Media (ICWSM)</i>. 2014:216–225.</li><li>Townsend L, Wallace C. Social Media Research: A Guide to Ethics. University of Aberdeen; 2016.</li></ol> |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Category A<br>Anti-amyloid<br>(n=733)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Category B<br>GLP-1 Agonists<br>(n=347) | Category C<br>Pipeline<br>(n=445)     |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Core AD clinical & scientific                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 57%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10%                                     | 29%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| GLP-1 / metabolic risk discourse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 48%                                     | 6%                                    |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lifestyle / brain health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12%                                     | 17%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Cellular / immune & inflammation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3%                                      | 19%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Medicare / access & coverage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 3%                                      | 0%                                    |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| APOE4 genetic risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0%                                      | 0%                                    |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| General public health & science                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 4%                                      | 8%                                    |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Personal narrative & caregiver                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20%                                     | 21%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Category                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Positive (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Neutral (%)                             | Negative (%)                          |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Cat C Pipeline (n=445)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 67%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 4%                                      | 30%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Cat B GLP-1 Agonists (n=347)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 59%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 8%                                      | 33%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Cat A Anti-amyloid (n=733)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 64%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14%                                     | 22%                                   |                                                                                                                                                                                                                                                                                                                                             |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                         |                                       | <p><b>CONTACT</b></p> <p>Dr Zain Hussain.<br/>Clinical Lecturer in Psychiatry<br/>University of Glasgow<br/><a href="mailto:zain.hussain@glasgow.ac.uk">zain.hussain@glasgow.ac.uk</a></p> <div> <b>ALZHEIMER'S ASSOCIATION</b>   <b>AAIC</b> 26</div> |                                   |                               |     |     |     |                                  |    |     |    |                          |    |     |     |                                  |    |    |     |                              |    |    |    |                    |    |    |    |                                 |    |    |    |                                |    |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |          |              |             |              |                        |     |    |     |                              |     |    |     |                            |     |     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |